CSPC Pharmaceutical Adds Capital Markets Veteran Zhang Yiwei to Board

CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.

CSPC Pharmaceutical Group has appointed Zhang Yiwei as an executive director effective 2 March 2026, adding to his current role as executive president in charge of the group’s securities affairs. Zhang brings more than 17 years of investment banking experience in equity and debt financing as well as mergers and acquisitions, gained at SDIC Securities and Huatai United Securities.

The company has signed a three-year service contract with Zhang, setting his remuneration at a monthly salary of RMB60,000 plus an annual director’s fee of HK$63,000 and a performance-based bonus. His appointment strengthens CSPC’s capital markets expertise at board level, signalling an emphasis on financing, investor relations and potential future transactions that could influence the group’s capital structure and growth strategy.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group operates across the pharmaceutical value chain, developing, manufacturing and marketing a range of drug products, with a focus on both domestic and international capital markets through active engagement with investors and regulators.

YTD Price Performance: 17.44%

Average Trading Volume: 122,129,057

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$113.9B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.